Adaptimmune Therapeutics PLC (ADAP)
1.08
-0.06
(-5.26%)
USD |
NASDAQ |
Apr 24, 16:00
1.08
0.00 (0.00%)
After-Hours: 20:00
Adaptimmune Therapeutics Free Cash Flow (Quarterly): -15.50M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | -15.50M |
September 30, 2023 | -45.45M |
June 30, 2023 | -45.00M |
March 31, 2023 | -39.80M |
December 31, 2022 | -1.386M |
September 30, 2022 | -58.40M |
June 30, 2022 | -50.21M |
March 31, 2022 | -61.52M |
December 31, 2021 | 129.89M |
September 30, 2021 | -46.87M |
June 30, 2021 | -33.24M |
March 31, 2021 | -47.82M |
December 31, 2020 | -30.45M |
September 30, 2020 | -17.12M |
June 30, 2020 | -25.44M |
March 31, 2020 | 16.51M |
December 31, 2019 | -13.14M |
September 30, 2019 | -29.94M |
Date | Value |
---|---|
June 30, 2019 | -35.18M |
March 31, 2019 | -37.31M |
December 31, 2018 | -31.90M |
September 30, 2018 | 8.599M |
June 30, 2018 | -36.60M |
March 31, 2018 | -49.19M |
December 31, 2017 | -23.29M |
September 30, 2017 | 11.86M |
June 30, 2017 | -26.97M |
March 31, 2017 | -40.93M |
December 31, 2016 | -4.551M |
September 30, 2016 | -17.46M |
June 30, 2016 | -17.70M |
March 31, 2016 | -21.25M |
September 30, 2015 | -7.128M |
December 31, 2014 | -3.422M |
September 30, 2014 | -13.62M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-61.52M
Minimum
Mar 2022
129.89M
Maximum
Dec 2021
-23.69M
Average
-33.24M
Median
Jun 2021
Free Cash Flow (Quarterly) Benchmarks
Biodexa Pharmaceuticals Plc | -- |
NuCana PLC | 0.3701M |
Autolus Therapeutics PLC | -26.31M |
Mereo BioPharma Group PLC | -- |
TC BioPharm (Holdings) PLC | -- |